Jubilant Life Sciences Ltd., an integrated global pharmaceuticals and life sciences company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through its contract manufacturing organization (CMO) subsidiary, Jubilant HollisterStier LLC, has signed a new contract with Eli Lilly for manufacturing of a treatment for COVID-19.
Lilly’s drug, Bamlanivimab, has been granted Emergency Use Authorization (EUA) by the FDA for emergency use as a treatment of COVID-19 and will be manufactured at Jubilant HollisterStier’s Spokane, WA facility.
“We are delighted to partner with our customers and contribute towards the fight against the COVID-19 pandemic,” said Pramod Yadav, chief executive officer, Jubilant Pharma Limited. “Our CMO business, an established player in the North American market, has strong capabilities in the manufacturing of sterile injectables—both liquid and lyophilization—and we are committed to continue exceeding expectations of our customers in this business.”
Lilly’s drug, Bamlanivimab, has been granted Emergency Use Authorization (EUA) by the FDA for emergency use as a treatment of COVID-19 and will be manufactured at Jubilant HollisterStier’s Spokane, WA facility.
“We are delighted to partner with our customers and contribute towards the fight against the COVID-19 pandemic,” said Pramod Yadav, chief executive officer, Jubilant Pharma Limited. “Our CMO business, an established player in the North American market, has strong capabilities in the manufacturing of sterile injectables—both liquid and lyophilization—and we are committed to continue exceeding expectations of our customers in this business.”
No comments:
Post a Comment
id="blogfeeds"><$BlogFeedsVertical$>
id="postfeeds"><$BlogItemFeedLinks$>